Cholestyramine resin absorbs and combines with the bile acids in the intestine to form an insoluble complex which is excreted in the feces. This results in a partial removal of bile acids from the enterophatic circulation by preventing their adsorption. The increased fecal loss of bile acids due to Cholestyramine resin administration leads to an increase oxidation of cholesterol to bile acids, a decrease in β-lipoprotein or low density lipoprotein plasma levels and decrease in serum cholesterol levels.